Outlook Therapeutics Inc. (NASDAQ: OTLK) has confirmed that it will release its Q4 2021 earnings on Wednesday, December 22, 2021.
What to look for
The company is already preparing for the commercial launch of ONS-5010 in 2022 and has commenced initiatives like drug substance production with FUJIFILM Diosynth Biotechnology. In addition, outlook Therapeutics is creating registration documents on a different path for regulatory approval in Europe and will submit them after finalizing FDA submissions with the US FDA.
Earnings: Stockearning’s estimated EPS for Q4 2021 is expected to be around $0.09 per share. In the third quarter, the company reported a net loss attributable to shareholders of $12.2 million or $0.07 per basic share. For the third quarter of 2021, the company had a net loss of $0.03 per share.
Revenue: At the end of the third quarter, the company had cash and investments of around $19.7 million. The company's cash is adequate to run its planned operations through December 2021.
Stock movement: Outlook Therapeutics shares have lost 47.4% since the last earnings release. However, following the earnings release, the company's shares have been UP six times in the last 12 quarters. So, the historical price reaction suggests a 50% probability of the share price going UP once Outlook Therapeutics reports its fiscal Q4 2021 quarterly earnings. According to the Stockearning algorithm, the predicted first-day move is 6%, while the predicted move on the seventh day is 28%.
What analysts are saying
H.C. Wainwright analyst Douglas Tsao reiterated his “buy” rating on the stock but raised his target price for the shares from $5 to $6. Tsao told investors in a research note that Outlook Therapeutics announced exceptional data showing Lytenava’s statistically significant superiority over Lucentis in subjects number with more than or equal to 15 letters corrected visual acuity and average BCVA score gain in both intent to treat and according to protocol populations. The analyst believes the 18% response rate difference leaves no doubt regarding Lytenava’s performance. Additionally, Tsai increased the probability of the drug to succeed in wet macular degeneration to around 80%.
Brookline Capital Markets analyst Kumaraguru Raja raised his price target in Outlook Therapeutics from $5 to $8 but maintained a “Buy” rating. The analyst said, “A new biologics license application (BLA) submission, under the PHSA 351(a) regulatory pathway, for wet AMD is planned in the calendar first quarter of 2022. Outlook is also working on filing for approval in Europe in 2022. We are increasing our estimates and our probability of success to 95%.”
Related News
Blackberry Limited (NYSE: BB) Fiscal Q3 2022 Earnings Expectations, Loss per share of $0.06
Academy Sports & Outdoor Inc. (NYSE: ASO) Earnings Expectations, Revenue Of $1.49 Billion In Q3 2021